The introduction of anti-vascular endothelial growth factor (VEGF) agents, such as ranibizumab and aflibercept, has revolutionized the treatment of several retinal diseases, including AMD, DME, and DR. The gene discussed is VEGFA; the disease is Abnormal retinal morphology.